ovarian cancer
Conditions
Interventions
chemo-sensitive group:Second generation capture methylation sequencing of tumor cells
chemo-resistant group:Second generation capture methylation sequencing of tumor cells
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
Female
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) ovarian serous adenocarcinoma; (2) chemotherapy-sensitive group: the patients were initially treated with platinum-based chemotherapy with clinically proven remission, and no recurrent lesions occurred after drug withdrawal for more than six months or until the end of information collection, which was called chemotherapy-sensitive type; (3) chemotherapeutic resistance group: that is, after satisfactory cell tumor reduction surgery and full amount of normal chemotherapy to achieve complete clinical remission, drug withdrawal for half a year, clinical evidence of tumor recurrence: no remission or aggravation of clinical symptoms, no decrease or increase of local mass in imaging examination, no change or increase of tumor markers.
Exclusion criteria
Exclusion criteria: Patients with ovarian cancer except serous adenocarcinoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| methylation; | — |
Countries
China
Contacts
Public ContactQiling Li
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed